TransCode Therapeutics Doses First Patient in Latest Cancer Clinical Trial Phase TransCode Therapeutics has announced that the first patient in Cohort 3 has been dosed in its Phase 1 clinical trial of TTX-MC138, its leading RNA therapeutic candidate for cancer treatment.

TransCode Therapeutics Doses First Patient in Latest Cancer Clinical Trial Phase #United_States #Boston #TTX-MC138 #TransCode_Therapeutics #Phase_1_Trial